Welcome to our dedicated page for MapLight Therapeutics SEC filings (Ticker: MPLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics director Robert C. Malenka reported small open-market sales of voting common stock mainly to cover taxes on vested restricted stock units. On February 2, 2026, he sold 7,039 shares at a weighted average price of $18.02, and on February 3, 2026, he sold 1 share at $18.00.
After these sales, he beneficially owns 358,233 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he has voting and dispositive power. The remaining securities he holds are still subject to a 180-day IPO lock-up following the final prospectus dated October 26, 2025.
MPLT insider Robert Malenka has filed a Form 144 to sell 1 share of common stock through Morgan Stanley Smith Barney LLC on or about 02/03/2026 on the NASDAQ, with an aggregate market value of $18.00. The share relates to restricted stock that vested on 01/23/2026 under a registered plan, received as consideration for services rendered.
Over the prior three months, Robert Malenka sold additional MPLT common shares, including 7,039 shares for gross proceeds of $126,835.04 on 02/02/2026 and 21,262 shares for gross proceeds of $394,469.63 on 01/29/2026, as well as other smaller transactions.
Robert Malenka has filed a notice of intent to sell common stock of MPLT under Rule 144. The filing indicates a planned sale of 7,039 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services on or around 02/02/2026, to be sold on NASDAQ.
These 7,039 shares were acquired on 01/23/2026 as restricted stock vesting under a registered plan, with consideration described as services rendered. The filing also lists recent sales by Malenka over the past three months, including common stock sales on 01/28/2026, 01/29/2026, and 01/30/2026 with disclosed gross proceeds for each transaction.
MapLight Therapeutics director Robert C. Malenka reported selling voting common stock primarily to cover taxes on restricted stock units. On January 28–30, 2026, he sold several blocks of shares at weighted average prices between about $18 and $19 per share.
After these sales, he beneficially owns 365,273 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power. The retained shares remain subject to a 180‑day IPO lock-up following the October 26, 2025 final prospectus.
Robert Malenka filed a notice of proposed sale of up to 6,612 shares of MPLT common stock under Rule 144. The shares, with an aggregate market value of $119,736.71, are expected to be sold on or about 01/30/2026 through Morgan Stanley Smith Barney on NASDAQ.
The 6,612 shares were acquired on 01/23/2026 as restricted stock vesting under a registered plan in exchange for services rendered. Over the past three months, Malenka has already sold 21,262 and 6,524 MPLT common shares on 01/29/2026 and 01/28/2026, generating gross proceeds of $394,469.63 and $121,689.56, respectively. MPLT had 45,373,033 common shares outstanding.
MapLight Therapeutics Chief Financial Officer reports routine tax-related share withholding. On January 27, 2026, 33,382 shares of voting common stock were withheld by the company at $17.98 per share to cover tax obligations tied to a restricted stock unit settlement.
After this transaction, the CFO beneficially owned 387,819 shares directly. The remaining securities are still subject to a lock-up agreement linked to MapLight’s initial public offering, restricting most transfers for 180 days after the final prospectus dated October 26, 2025.
MapLight Therapeutics Chief Scientific Officer Lillie James Woodruff reported a tax-withholding transaction in company stock. On January 27, 2026, 45,055 shares of Voting Common Stock were withheld at $17.98 per share to cover taxes from restricted stock unit settlement, a non-open-market event coded “F.”
After this withholding, Woodruff beneficially owned 291,132 shares directly. The remaining securities continue to be subject to an IPO lock-up agreement, under which Woodruff agreed, with certain exceptions, not to sell or transfer issuer securities for 180 days following the final IPO prospectus dated October 26, 2025.
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported a tax-related share withholding connected to restricted stock units. On January 27, 2026, 42,099 shares of Voting Common Stock were withheld at $17.98 per share to satisfy tax obligations.
After this withholding, Kreitzer directly beneficially owns 253,908 shares of MapLight Therapeutics stock. The remaining securities he holds are subject to a lock-up agreement tied to the company’s initial public offering, restricting most sales for 180 days after the October 26, 2025 final IPO prospectus.
MapLight Therapeutics CEO Christopher A. Kroeger reported a tax-related share withholding tied to equity compensation. On January 27, 2026, 204,146 shares of MapLight voting common stock were withheld by the company at a price of $17.98 per share to satisfy tax obligations from restricted stock unit settlements.
Following this transaction, Kroeger held 1,626,606 shares of voting common stock directly. In addition, 101,190 shares were held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse serve as co-trustees with voting and dispositive power. The retained securities remain subject to a lock-up agreement lasting 180 days after the October 26, 2025 final IPO prospectus, limiting sales or transfers except for certain permitted exceptions.
MapLight Therapeutics officer Jonathan Gillis, who serves as CAAO and PAO, reported a tax-related share withholding on January 27, 2026. The transaction involved 22,050 shares of Voting Common Stock (code F) at $17.98 per share, used to satisfy tax withholding on restricted stock unit settlements.
Following this withholding, Gillis beneficially owned 248,503 shares directly. The remaining securities he holds are still subject to a lock-up agreement related to MapLight’s initial public offering, restricting most transfers for 180 days after the final prospectus dated October 26, 2025.
FAQ
What is the current stock price of MapLight Therapeutics (MPLT)?
What is the market cap of MapLight Therapeutics (MPLT)?
